The Moghimi Laboratory investigates ways to enhance chimeric antigen receptor (CAR) T-cell therapy to expand its use in treatment for pediatric neuroblastoma and leukemia. CAR T-cell therapy uses a patient’s own immune system T-cells, engineering them to recognize and destroy cancer cells. The goal of our laboratory at CHLA is to translate our research directly into precise, safer CAR T-cell therapies that can improve patients’ response to treatment.
Funding
PI, Cure Search Scholar Award
07/1/2024-6/31/2026
Tuning gated CAR T cells for pediatric tumors
PI, St. Baldrick’s Career Development Award
07/1/2021-6/31/2026
Tuning gated CAR T cells for pediatric tumors
PI, CAL Career Development Award
07/1/2021-6/31/2024
Developing gated CAR T cells for AML
Co-PI, California Institute for Regenerative Medicine (CIRM) CLIN1
03/01/2024-03/01/2027
Development of TGF-b-resistant CAR T-cells
Collaborate With Us
Please contact us to learn more about working with the lab:
bmoghimi@chla.usc.edu [Babak Moghimi, MD]
sbarman@usc.edu [Shawn Barman]
